Jean Pierre Bizzari

Biography

Dr Bizzari has served as EVP, group head, and clinical oncology development (US, Europe, and Asia/Japan) at Celgene from 2008 to 2015. Prior to this, he spent 15 years as vice president clinical development at Rhône-Poulenc Rorer, Aventis and Sanofi-Aventis and has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Revlimid®, Vidaza®, Abraxane®, Irinotecan® (CPT-11). Dr Bizzari is a world-renowned oncology expert and is a member of the scientific advisory board of the French National Cancer Institute (INCa), and is chair of the New Drug Advisory Committee at the European Organization of Research and Treatment of Cancer (EORTC). He serves as director of the boards of several biotech companies; Transgene, Onxeo, Iteos, Halozyme Therapeutics and Pieris Pharmaceuticals. Dr Bizzari has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses. He joined the pharmaceutical industry in 1983 as head of oncology at the Institut de Recherches Internationales Servier(France). Dr Bizzari holds a medical degree specialised in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal McGill Cancer Center in Canada. Dr Bizzari has served as a director in the company since May 2016. He is an independent director of the board. Dr Bizzari has served as EVP, group head, and clinical oncology development (US, Europe, and Asia/Japan) at Celgene from 2008 to 2015. Prior to this, he spent 15 years as vice president clinical development at Rhône-Poulenc Rorer, Aventis and Sanofi-Aventis and has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Revlimid®, Vidaza®, Abraxane®, Irinotecan® (CPT-11). Dr Bizzari is a world-renowned oncology expert and is a member of the scientific advisory board of the French National Cancer Institute (INCa), and is chair of the New Drug Advisory Committee at the European Organization of Research and Treatment of Cancer (EORTC). He serves as director of the boards of several biotech companies; Transgene, Onxeo, Iteos, Halozyme Therapeutics and Pieris Pharmaceuticals. Dr Bizzari has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses. He joined the pharmaceutical industry in 1983 as head of oncology at the Institut de Recherches Internationales Servier(France). Dr Bizzari holds a medical degree specialised in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal McGill Cancer Center in Canada. Dr Bizzari has served as a director in the company since May 2016. He is an independent director of the board.

Research Interest

Business Management